OpenLegislation

Commission Implementing Regulation (EU) No 564/2013 of 18 June 2013 on the fees and charges payable to the European Chemicals Agency pursuant to Regulation (EU) No 528/2012 of the European Parliament and of the Council concerning the making available on the market and use of biocidal products (Text with EEA relevance) (revoked) in Wales

EU Regulation No 564/2013 · Adopted 18 June 2013 · Extends to United Kingdom

Original text. legislation.gov.uk does not revise this item, so later amendments are not shown here. Changes made to it are listed under each provision when known.

Commission Implementing Regulation (EU) No 564/2013

of 18 June 2013

on the fees and charges payable to the European Chemicals Agency pursuant to Regulation (EU) No 528/2012 of the European Parliament and of the Council concerning the making available on the market and use of biocidal products

(Text with EEA relevance) (revoked)

F1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annotations to the whole text

Textual amendments

F1

Regulation revoked (1.1.2024) by Retained EU Law (Revocation and Reform) Act 2023 (c. 28), ss. 1(1), 22(3), Sch. 1 Pt. 2 (with s. 1(3)(4)); S.I. 2023/1363, reg. 2

Contents

  1. Chapter I: FEES Repealed
  2. 1Fees for work in relation to active substances Repealed
  3. 2Fees for work in relation to Union authorisation of biocidal products Repealed
  4. 3Other fees Repealed
  5. 4Fees for appeals against a decision of the Agency under Article 77 of Regulation (EU) No 528/2012 Repealed
  6. 5Reimbursement possibility for alternatives to approved active substances fulfilling one of the exclusion criteria Repealed
  7. Chapter II: SUPPORT FOR SMEs Repealed
  8. 6Recognition of SME status Repealed
  9. 7Fee Reductions Repealed
  10. Chapter III: PAYMENTS Repealed
  11. 8Mode of payment Repealed
  12. 9Identification of the payment Repealed
  13. 10Date of payment Repealed
  14. 11Insufficient payment Repealed
  15. 12Refund of amounts paid in excess Repealed
  16. 13Refunds of amounts in case of applications rejected before or during validation or withdrawn during the assessment Repealed
  17. Chapter IV: FINAL PROVISIONS Repealed
  18. 14Reimbursement of rapporteurs Repealed
  19. 15Charges Repealed
  20. 16Provisional estimate Repealed
  21. 17Review Repealed
  22. 18Article 18 Repealed
  23. Signature
  24. Annex IAnnex I Repealed
  25. Annex IIAnnex II Repealed
  26. Annex IIIAnnex III Repealed

1Fees for work in relation to active substancesF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

2Fees for work in relation to Union authorisation of biocidal productsF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3Other feesF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

4Fees for appeals against a decision of the Agency under Article 77 of Regulation (EU) No 528/2012F1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

5Reimbursement possibility for alternatives to approved active substances fulfilling one of the exclusion criteriaF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

6Recognition of SME statusF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

7Fee ReductionsF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

8Mode of paymentF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

9Identification of the paymentF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10Date of paymentF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

11Insufficient paymentF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

12Refund of amounts paid in excessF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

13Refunds of amounts in case of applications rejected before or during validation or withdrawn during the assessmentF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

14Reimbursement of rapporteursF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

15ChargesF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

16Provisional estimateF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

17ReviewF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

18F1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Signature

F1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annex IF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annex IIF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Annex IIIF1

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .